Uncovering 3 Stocks Including Palo Alto Networks That May Be Trading Below Intrinsic Value Estimates

As the U.S. stock market begins the week on a high note, buoyed by gains across major indices and ongoing developments in trade and inflation data, investors are keenly observing opportunities amid economic uncertainties like the prolonged government shutdown. In this environment, identifying stocks that may be trading below their intrinsic value can offer potential for growth, making it crucial to consider factors such as financial health and market position when evaluating investment prospects.

Top 10 Undervalued Stocks Based On Cash Flows In The United States

Click here to see the full list of 182 stocks from our Undervalued US Stocks Based On Cash Flows screener.

Below we spotlight a couple of our favorites from our exclusive screener.

Palo Alto Networks (PANW)

Overview: Palo Alto Networks, Inc. is a global provider of cybersecurity solutions with a market cap of approximately $143.37 billion.

Operations: The company's revenue primarily comes from its Security Software & Services segment, which generated approximately $9.22 billion.

Estimated Discount To Fair Value: 10%

Palo Alto Networks is trading at US$211.82, below its estimated fair value of US$235.4, suggesting it may be undervalued based on cash flows. Despite a decline in profit margins from 32.1% to 12.3%, earnings are projected to grow faster than the US market at 17.3% annually. The company's recent innovations in AI-driven security solutions and strong SASE growth underscore its leadership in cybersecurity, potentially enhancing future cash flow generation.

• Our earnings growth report unveils the potential for significant increases in Palo Alto Networks' future results.
• Dive into the specifics of Palo Alto Networks here with our thorough financial health report.

Workday (WDAY)

Overview: Workday, Inc. offers enterprise cloud applications globally and has a market cap of approximately $64.40 billion.

Operations: The company generates revenue primarily from its Cloud Applications segment, which amounts to $8.96 billion.

Estimated Discount To Fair Value: 27.7%

Workday is trading at US$241.2, which is below its estimated fair value of US$333.66, indicating potential undervaluation based on cash flows. Despite a drop in profit margins from 19.6% to 6.5%, earnings are expected to grow significantly at 32.1% annually over the next three years, outpacing the broader US market growth rate of 15.5%. Recent partnerships and integrations with companies like Flywire and Lattice enhance Workday's platform capabilities, potentially driving future cash flow improvements.

• The growth report we've compiled suggests that Workday's future prospects could be on the up.
• Click to explore a detailed breakdown of our findings in Workday's balance sheet health report.

AbbVie (ABBV)

Overview: AbbVie Inc. is a research-based biopharmaceutical company involved in the research, development, manufacture, commercialization, and sale of medicines and therapies globally, with a market cap of approximately $409.95 billion.

Operations: AbbVie's revenue primarily comes from its Innovative Medicines and Therapies segment, which generated $58.33 billion.

Estimated Discount To Fair Value: 44.2%

AbbVie, trading at US$232.06, is significantly below its estimated fair value of US$416.07, suggesting it may be undervalued based on cash flows. Despite high debt levels and declining profit margins from 9.6% to 6.4%, earnings are projected to grow substantially at 30.7% annually over the next three years, surpassing the US market average of 15.5%. Recent positive trial results for RINVOQ in rheumatoid arthritis could bolster future revenue streams despite slower revenue growth forecasts compared to the market.

• Our expertly prepared growth report on AbbVie implies its future financial outlook may be stronger than recent results.
• Delve into the full analysis health report here for a deeper understanding of AbbVie.

Taking Advantage

• Dive into all 182 of the Undervalued US Stocks Based On Cash Flows we have identified here.
• Got skin in the game with these stocks? Elevate how you manage them by using Simply Wall St's portfolio, where intuitive tools await to help optimize your investment outcomes.
• Join a community of smart investors by using Simply Wall St. It's free and delivers expert-level analysis on worldwide markets.

Searching for a Fresh Perspective?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.
• Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com